Lonza to buy Merck KGaA’s US CDMO network
Submitted by:
Andrew Warmington
Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US
Feature article - Why one purity number cannot carry a quality claim
Submitted by:
Andrew Warmington
Cristian Bucsa, founder of ReviveLab, examines why chromatographic purity, identity and assay should remain separate
Esteve CDMO in major China investment
Submitted by:
Andrew Warmington
Esteve CDMO, the CDMO arm of Spanish pharmaceutical CDMO, is planning to spend over $80
CDMOs grow in ADCs
Submitted by:
Andrew Warmington
Reflecting the ongoing boom in the development antibody-drug conjugates (ADCs), two Western CDMOs announced expansions
SK Pharmteco in $200 million expansion
Submitted by:
Andrew Warmington
SK Pharmteco is to spend over $200 million to expand and upgrade its development and
Flamma buys Lundbeck site
Submitted by:
Andrew Warmington
Italian CDMO Flamma has entered into an agreement to acquire Lundbeck Pharmaceuticals Italy (LuPI) from
Homochirality behind Nobel Chemistry win
Submitted by:
Andrew Warmington
Henri Kagan of Université Paris-Sud and Kenso Soai of Tokyo University of Science have won
Esteve expands in US
Submitted by:
Andrew Warmington
Spain’s Esteve has approved an additional $17.5 million in capacity expansion and containment capabilities at
Feature article - Toward greener real-time peptide manufacturing with inline RI monitoring
Submitted by:
Andrew Warmington
Tamara Murusidze of Vaisala looks at the advantages of inline refractive index monitoring in process
Unlocking innovation through industrial photochemistry
Submitted by:
Andrew Warmington